| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,480 | 4,800 | 16:01 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 22,200 | 30 | |||
| 20,000 | 83 | |||
| 16,000 | 532 | |||
| 15,000 | 15 | |||
| 5,100 | 953 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 953 | 4,780 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.014 | 0,804 | 1.619 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IN BRIEF: 4basebio appoints Richard Bungay chief financial officer | 1 | Alliance News | ||
| Do | 4basebio Names Richard Bungay CFO; Announces Board Changes | 3 | RTTNews | ||
| Do | 4basebio taps Richard Bungay as new finance chief | 1 | Sharecast | ||
| Do | 4basebio Plc - Appointment of Chief Financial Officer and Board Changes | 253 | PR Newswire | 4basebio Plc - Appointment of Chief Financial Officer and Board Changes
PR Newswire
LONDON, United Kingdom, May 14
4basebio... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| Di | IN BRIEF: 4basebio launches high-capacity single-stranded DNA platform | 9 | Alliance News |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 15:09 | EQS-HV: Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Ladenburg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS Group (DE) | EQS-News: Heidelberg Pharma AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in... ► Artikel lesen | |
| 15:06 | Oncotelic Therapeutics, Inc.: Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress | GlobeNewswire (Europe) | Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biotechnology company focused on oncology, AI-enabled... ► Artikel lesen | |
| 14:20 | Pulmatrix Inc.: Pulmatrix Announces First Quarter 2026 Financial Results | PR Newswire | Announced merger agreement with Eos SENOLYTIX in March
Closed private placement of preferred stock
FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc.... ► Artikel lesen | |
| 14:06 | UroGen Pharma Ltd.: UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC | GlobeNewswire (Europe) | PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced... ► Artikel lesen | |
| 14:06 | BioCardia, Inc.: BioCardia Reports First Quarter 2026 Business Highlights and Financial Results | GlobeNewswire (Europe) | SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases... ► Artikel lesen |